Candida auris is a recently described pathogenic fungus that is causing invasive 24 outbreaks on all continents. The fungus is of high concern given the numbers of multidrug-25 resistant strains that have been isolated in distinct sites across the globe. The fact that its 26 diagnosis is still problematic suggests that the spreading of the pathogen remains 27 underestimated. Notably, the molecular mechanisms of virulence and antifungal resistance 28 employed by this new species are largely unknown. In the present work, we compared two 29 clinical isolates of C. auris with distinct drug susceptibility profiles and a Candida albicans 30 reference strain using a multi-omics approach. Our results show that, despite the distinct 31 drug-resistance profile, both C. auris strains appear to be very similar, albeit with a few 32 notable differences. However, when compared to C. albicans both C. auris strains have 33 major differences regarding their carbon utilization and downstream lipid and protein 34 content, suggesting a multi-factorial mechanism of drug resistance. The molecular profile 35 displayed by C. auris helps to explain the antifungal resistance and virulence phenotypes of 36 this new emerging pathogen.
37Importance: Candida auris was firstly described in Japan in 2009 and has now been the 38 cause of significant outbreaks across the globe. The high number of isolates that are 39 resistant to one or more antifungals, as well as the high mortality rates from patients with 40 bloodstream infections, has caught the attention of the medical mycology, infectious 41 disease and public health communities to this pathogenic fungus. In the current work, we 42 performed a broad multi-omics approach on two clinical isolates isolated in New York, the 43 most affected area in the USA and found that the omic profile of C. auris differs 44 3 significantly from C. albicans. Besides our insights into C. auris carbon utilization and 45 lipid and protein content, we believe that the availability of these data will enhance our 46 ability to combat this rapidly emerging pathogenic yeast.
48Candida auris is an emerging pathogenic fungus that was firstly described in 2009 after 49 being isolated from the ear discharge of a patient in Tokyo, Japan (1). After the new species 50 identification, a study in South Korea reported a misidentified C. auris strain isolated in 51 1996, which then became the first known case of human C. auris infection (2). Despite the 52 fact that bloodstream infections are the main cause of mortality among Candida spp 53 infections, C. auris strains have been isolated from various sites such as respiratory tract, 54 bones, and central nervous system (3) as well as on a variety of abiotic surfaces (4), which 55 suggests a metabolic plasticity to survive in distinct environments. The reports of C. auris 56 outbreaks in all continents suggest that this pathogen is spreading rapidly across the globe 57 and many of the isolated strains are resistant to at least one class of antifungals, or even 58 multidrug-re...